Risk-Stratified Management of Antibody-Drug Conjugates Drug–Related Neutropenia: Integrating Clinical Trial Meta-Summary and Existing Guideline Principles
Cancer Research and Treatment · 2026
DOI: 10.4143/crt.2025.533 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cancer Research and Treatment, 2026. Verfasst von Zheling Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzho…. Hauptthemen laut MEDLINE: Neutropenia, Immunoconjugates, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Zhejiang Provincial Science and Technology Department Leading Goose Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
Anti-tumor drugs have developed rapidly in recent years. Antibody-drug conjugates (ADCs), as a novel class of targeted biologics, demonstrate significant survival benefits but inevitably cause treatment-related toxicities, with hematologic toxicity—particularly severe neutropenia (grade ≥ 3)—representing the most prevalent and clinically consequential adverse effect. Currently, no standardized ADC-specific neutropenia management guidelines exist, resulting in fragmented prevention strategies where clinical practice relies on extrapolation from chemotherapy protocols and reactive approaches (e.g., post-onset growth factor support). This study aims to address this gap by proposing a structured preventive framework for ADC-induced neutropenia.Materials and Methods We conducted a systematic meta-summary of neutropenia data from clinical trials involving ADCs. This evidence was integrated with established principles from chemotherapy-induced neutropenia guidelines and expert consensus. The analysis focused on drug-specific risk profiles, patient-related factors, and evidence-based interventional strategies.
Results
We developed a risk-adapted preventive strategy centered on a “planning for a rainy day” approach. The framework incorporates: risk stratification based on the specific ADC drug and patient factors; primary prophylaxis with long-acting granulocyte colony-stimulating factor for high-risk patients; secondary prevention strategies for subsequent treatment cycles; and dynamic monitoring of absolute neutrophil counts around days 5-7 post-infusion.
Conclusion
Shifting from a reactive to a proactive, personalized prevention paradigm can potentially reduce the incidence of severe neutropenia, subsequent treatment interruptions, and infection-related mortality. This framework provides actionable guidance for standardizing ADC toxicity management and underscores the importance of prioritizing hematologic safety in future ADC development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
- School of Public Health, Hangzhou Medical College, Hangzhou, China.
- Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China. yangliuqq2003@163.com.
- School of Public Health, Hangzhou Medical College, Hangzhou, China. yangliuqq2003@163.com.
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- Zhejiang Provincial Science and Technology Department Leading Goose Project
- National Natural Science Foundation of China
Zitieren
APA
Chen, Z., Zhao, K., Jiang, J., & Yang, L. (2026). Risk-Stratified Management of Antibody-Drug Conjugates Drug–Related Neutropenia: Integrating Clinical Trial Meta-Summary and Existing Guideline Principles. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.533
Vancouver
Chen Z, Zhao K, Jiang J, Yang L. Risk-Stratified Management of Antibody-Drug Conjugates Drug–Related Neutropenia: Integrating Clinical Trial Meta-Summary and Existing Guideline Principles. Cancer Research and Treatment. 2026. doi:10.4143/crt.2025.533
BibTeX
@article{Chen2026,
author = {Chen, Zheling and Zhao, Keju and Jiang, Jiahong and Yang, Liu},
title = {Risk-Stratified Management of Antibody-Drug Conjugates Drug–Related Neutropenia: Integrating Clinical Trial Meta-Summary and Existing Guideline Principles},
journal = {Cancer Research and Treatment},
year = {2026},
doi = {10.4143/crt.2025.533}
}
EUVIMED